Michael Schmidt
Stock Analyst at Guggenheim
(4.94)
# 33
Out of 5,124 analysts
116
Total ratings
72.53%
Success rate
54.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $12 → $18 | $12.51 | +43.88% | 2 | Feb 6, 2026 | |
| NBTX Nanobiotix | Maintains: Buy | $8 → $26 | $20.85 | +24.70% | 3 | Feb 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Buy | $92 → $160 | $97.49 | +64.12% | 5 | Jan 20, 2026 | |
| CTMX CytomX Therapeutics | Initiates: Buy | $10 | $5.67 | +76.37% | 1 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Buy | $16 → $34 | $19.55 | +73.91% | 2 | Jan 8, 2026 | |
| IMNM Immunome | Maintains: Buy | $25 → $35 | $24.88 | +40.68% | 4 | Dec 16, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $5.68 | +111.27% | 1 | Nov 7, 2025 | |
| INCY Incyte | Upgrades: Buy | $125 | $108.39 | +15.32% | 7 | Nov 3, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $30.90 | +39.16% | 3 | Sep 23, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Buy | $10 | $4.01 | +149.38% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $10.42 | +72.74% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $6.52 | +84.05% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $365 | $353.92 | +3.13% | 4 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $13.48 | +11.28% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $37.08 | -54.15% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $21.86 | +105.86% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $21.35 | -29.74% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $79.59 | -34.67% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $8.92 | +12.11% | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $21.01 | +52.31% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $6.67 | +109.90% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $17.10 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $43.90 | -4.33% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $1.70 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $6.65 | +200.75% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $2.39 | +234.73% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.98 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $112 | $7.03 | +1,493.17% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.77 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.93 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.69 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $11.61 | +192.85% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $12.29 | +103.42% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $2.19 | +1,087.21% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.57 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $26.53 | +201.55% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.86 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.84 | +43.23% | 2 | Nov 7, 2017 |
Tango Therapeutics
Feb 6, 2026
Maintains: Buy
Price Target: $12 → $18
Current: $12.51
Upside: +43.88%
Nanobiotix
Feb 6, 2026
Maintains: Buy
Price Target: $8 → $26
Current: $20.85
Upside: +24.70%
Revolution Medicines
Jan 20, 2026
Maintains: Buy
Price Target: $92 → $160
Current: $97.49
Upside: +64.12%
CytomX Therapeutics
Jan 20, 2026
Initiates: Buy
Price Target: $10
Current: $5.67
Upside: +76.37%
Monte Rosa Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $16 → $34
Current: $19.55
Upside: +73.91%
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $25 → $35
Current: $24.88
Upside: +40.68%
Foghorn Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $5.68
Upside: +111.27%
Incyte
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $108.39
Upside: +15.32%
Genmab
Sep 23, 2025
Upgrades: Buy
Price Target: $43
Current: $30.90
Upside: +39.16%
ADC Therapeutics
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $4.01
Upside: +149.38%
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $10.42
Upside: +72.74%
Aug 12, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $6.52
Upside: +84.05%
Aug 7, 2025
Maintains: Buy
Price Target: $350 → $365
Current: $353.92
Upside: +3.13%
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $13.48
Upside: +11.28%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $37.08
Upside: -54.15%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $21.86
Upside: +105.86%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $21.35
Upside: -29.74%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $79.59
Upside: -34.67%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $8.92
Upside: +12.11%
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $21.01
Upside: +52.31%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $6.67
Upside: +109.90%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $17.10
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $43.90
Upside: -4.33%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $1.70
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $6.65
Upside: +200.75%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.39
Upside: +234.73%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $31.98
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $112
Current: $7.03
Upside: +1,493.17%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.77
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.93
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.69
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $11.61
Upside: +192.85%
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $12.29
Upside: +103.42%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $2.19
Upside: +1,087.21%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.57
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $26.53
Upside: +201.55%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $11.86
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.84
Upside: +43.23%